Ab­b­Vie staves off an­oth­er US Hu­mi­ra knock­off to 2023 as Eu­ro­pean launch looms

Just a few days be­fore Hu­mi­ra knock­offs are set to de­but in parts of Eu­rope, Ab­b­Vie has set­tled an­oth­er round of IP lit­i­ga­tion for its iron­clad mega-block­buster fran­chise in the US.

This time the deal is with San­doz, No­var­tis’ gener­ic arm, which has agreed to launch its biosim­i­lar in the US lat­er in 2023 than oth­er com­peti­tors will have, per their pre­vi­ous agree­ments with Ab­b­Vie.

Here’s what the suc­ces­sion of launch­es will look like:

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN